Why the Market Dipped But Entera Bio Ltd. (ENTX) Gained Today
https://www.zacks.com/stock/news/2258103/why-the-market-dipped-but-entera-bio-ltd-entx-gained-today?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2258103
Apr 18, 2024 - In the closing of the recent trading day, Entera Bio Ltd. (ENTX) stood at $2.24, denoting a +0.9% change from the preceding trading day.
0
Takeda said to have left industry trade group BIO
https://seekingalpha.com/news/4094442-takeda-leaves-industry-trade-group-bio?source=feed_sector_healthcare
Apr 25, 2024 - Takeda Pharmaceutical (TAK) joins Pfizer (PFE) in leaving the Biotechnology Innovation Organization, the top biotech lobbying group. Read more here.
0
Tourmaline Bio director discloses purchase of stake worth $3.25M
https://seekingalpha.com/news/4061462-tourmaline-bio-director-discloses-purchase-of-stake-worth-325m?source=feed_sector_healthcare
Feb 01, 2024 - This article discusses insider trading at Tourmaline Bio (TRML), with its director Mark McDade acquiring 100,000 company shares for $3.25 million.
0
Bio-Rad Laboratories (BIO) to Post Q4 Earnings: What Awaits?
https://www.zacks.com/stock/news/2221181/bio-rad-laboratories-bio-to-post-q4-earnings-what-awaits?cid=CS-ZC-FT-analyst_blog|earnings_preview-2221181
Feb 05, 2024 - Ongoing weakness in the biopharma end markets, impacting the sales of Life Science tools and bioprocessing products, are likely to have impeded Bio-Rad's (BIO) Q4 revenues.
0
Why Bluebird Bio Stock Dived Into the Red on Tuesday
https://www.fool.com/investing/2024/03/05/why-bluebird-bio-stock-dived-into-the-red-on-tuesd/?source=iedfolrf0000001
Mar 05, 2024 - The biotech has had a tough time of it over the past few years; a pundit's revised take on the company won't improve that situation.
0
Gritstone bio Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates
https://www.zacks.com/stock/news/2236362/gritstone-bio-inc-grts-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2236362
Mar 05, 2024 - Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 27.78% and 116.31%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
0
Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know
https://www.zacks.com/stock/news/2237527/passage-bio-inc-pasg-is-up-24-26-in-one-week-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_10-2237527
Mar 07, 2024 - Does Passage Bio, Inc. (PASG) have what it takes to be a top stock pick for momentum investors? Let's find out.
0
Is Bluebird Bio Stock a Buy Now?
https://www.fool.com/investing/2024/03/13/is-bluebird-bio-stock-a-buy-now/?source=iedfolrf0000001
Mar 13, 2024 - Are you feeling brave?
0
Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology
https://www.zacks.com/stock/news/2240226/allogene-allo-inks-deal-with-arbor-bio-for-crispr-technology?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240226
Mar 13, 2024 - Allogene (ALLO) intends to combine its next generation AlloCAR T platform with Arbor Biotechnologies' proprietary CRISPR gene therapy technology to develop therapies for autoimmune diseases.
0
Why Bluebird Bio Stock Flew Higher Than the Market Today
https://www.fool.com/investing/2024/03/18/why-bluebird-bio-stock-flew-higher-than-the-market/?source=iedfolrf0000001
Mar 18, 2024 - The company was thrown a financial lifeline.
0